Get the Stockscreener App
2.35
1.26%
-0.03
Jaguar Health Inc stock is traded at $2.35, with a volume of 27,156.
It is down -1.26% in the last 24 hours and down -22.95% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$2.38
Open:
$2.38
24h Volume:
27,156
Relative Volume:
0.19
Market Cap:
$3.83M
Revenue:
$10.48M
Net Income/Loss:
$-37.74M
P/E Ratio:
-0.1452
EPS:
-16.1846
Net Cash Flow:
$-29.03M
1W Performance:
+1.29%
1M Performance:
-22.95%
6M Performance:
-89.06%
1Y Performance:
-93.33%
1-Day Range:
$2.33
$2.40
1-Week Range:
$2.27
$2.44
52-Week Range:
$2.27
$35.25
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
2.35 | 3.18M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.50 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.54 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.83 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
588.88 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.00 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
What drives Jaguar Health Inc. stock priceExplosive market performance - Autocar Professional
Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Sentinel-Standard
What analysts say about Jaguar Health Inc. stockSkyrocketing investment returns - jammulinksnews.com
Jaguar Health Inc. Stock Analysis and ForecastAccelerated investment success - jammulinksnews.com
Is Jaguar Health Inc. a good long term investmentTremendous return rates - Autocar Professional
Form DEF 14A Jaguar Health, Inc. For: Aug 19 - StreetInsider
Published on: 2025-07-20 16:31:40 - Autocar Professional
Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC - FinancialContent
Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market - Stock Titan
Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer - ACCESS Newswire
Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS In - El Paso Times
Groundbreaking Deal: Peru Grants Access to Sacred Coca Plant for Mental Health Drug Research - Stock Titan
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 36% Hiding - 富途牛牛
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review - ACCESS Newswire
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Lohud
Investors Give Jaguar Health, Inc. (NASDAQ:JAGX) Shares A 43% Hiding - simplywall.st
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient - Worcester Telegram
Breakthrough Treatment Reduces Parenteral Nutrition by 27% in Orphan Disease PatientsNew Clinical Data - Stock Titan
Jaguar Health (JAGX) Announces $3.37M At-The-Market Stock Offering | JAGX SEC FilingForm 424B5 - Stock Titan
Jaguar Health (JAGX) Adopts Cryptocurrency as Treasury Asset | JAGX Stock News - GuruFocus
Jaguar Health considers cryptocurrency for treasury reserves - Investing.com
Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | - GuruFocus
Jaguar Health (JAGX) Targets EU Approval for Canalevia in Dogs | JAGX Stock News - GuruFocus
Jaguar Health seeks EU approval for dog diarrhea treatment - Investing.com
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - The Columbus Dispatch
Jaguar Health extends maturity date for $2.57 million in notes By Investing.com - Investing.com Nigeria
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - The Holland Sentinel
Jaguar Health reports 25% enrollment in phase 2 MVID study - Investing.com
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Marco Eagle
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.24%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):